vs

Side-by-side financial comparison of ITT INC. (ITT) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.

ITT INC. is the larger business by last-quarter revenue ($1.1B vs $622.0M, roughly 1.7× Royalty Pharma plc). Royalty Pharma plc runs the higher net margin — 34.4% vs 12.5%, a 21.9% gap on every dollar of revenue. On growth, ITT INC. posted the faster year-over-year revenue change (13.5% vs 4.8%). Over the past eight quarters, ITT INC.'s revenue compounded faster (7.6% CAGR vs 4.6%).

ITT Inc., formerly ITT Corporation, is an American manufacturing company based in Stamford, Connecticut. The company produces specialty components for the aerospace, transportation, energy, and industrial markets. ITT's three business units are Industrial Process, Motion Technologies, and Connect and Control Technologies.

Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.

ITT vs RPRX — Head-to-Head

Bigger by revenue
ITT
ITT
1.7× larger
ITT
$1.1B
$622.0M
RPRX
Growing faster (revenue YoY)
ITT
ITT
+8.7% gap
ITT
13.5%
4.8%
RPRX
Higher net margin
RPRX
RPRX
21.9% more per $
RPRX
34.4%
12.5%
ITT
Faster 2-yr revenue CAGR
ITT
ITT
Annualised
ITT
7.6%
4.6%
RPRX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ITT
ITT
RPRX
RPRX
Revenue
$1.1B
$622.0M
Net Profit
$131.7M
$214.2M
Gross Margin
35.5%
Operating Margin
17.0%
62.4%
Net Margin
12.5%
34.4%
Revenue YoY
13.5%
4.8%
Net Profit YoY
3.7%
2.9%
EPS (diluted)
$1.64
$0.49

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ITT
ITT
RPRX
RPRX
Q4 25
$1.1B
$622.0M
Q3 25
$999.1M
$609.3M
Q2 25
$972.4M
$578.7M
Q1 25
$913.0M
$568.2M
Q4 24
$929.0M
$593.6M
Q3 24
$885.2M
$564.7M
Q2 24
$905.9M
$537.3M
Q1 24
$910.6M
$568.0M
Net Profit
ITT
ITT
RPRX
RPRX
Q4 25
$131.7M
$214.2M
Q3 25
$126.9M
$288.2M
Q2 25
$121.0M
$30.2M
Q1 25
$108.4M
$238.3M
Q4 24
$127.0M
$208.2M
Q3 24
$161.1M
$544.0M
Q2 24
$119.2M
$102.0M
Q1 24
$111.0M
$4.8M
Gross Margin
ITT
ITT
RPRX
RPRX
Q4 25
35.5%
Q3 25
35.6%
Q2 25
35.7%
Q1 25
34.6%
Q4 24
34.1%
Q3 24
35.5%
Q2 24
34.9%
Q1 24
33.0%
Operating Margin
ITT
ITT
RPRX
RPRX
Q4 25
17.0%
62.4%
Q3 25
18.0%
70.1%
Q2 25
18.0%
36.3%
Q1 25
16.5%
94.0%
Q4 24
17.2%
60.9%
Q3 24
23.5%
Q2 24
17.6%
50.2%
Q1 24
16.4%
-13.0%
Net Margin
ITT
ITT
RPRX
RPRX
Q4 25
12.5%
34.4%
Q3 25
12.7%
47.3%
Q2 25
12.4%
5.2%
Q1 25
11.9%
41.9%
Q4 24
13.7%
35.1%
Q3 24
18.2%
96.3%
Q2 24
13.2%
19.0%
Q1 24
12.2%
0.8%
EPS (diluted)
ITT
ITT
RPRX
RPRX
Q4 25
$1.64
$0.49
Q3 25
$1.62
$0.67
Q2 25
$1.52
$0.07
Q1 25
$1.33
$0.55
Q4 24
$1.54
$0.46
Q3 24
$1.96
$1.21
Q2 24
$1.45
$0.23
Q1 24
$1.35
$0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ITT
ITT
RPRX
RPRX
Cash + ST InvestmentsLiquidity on hand
$1.7B
$618.7M
Total DebtLower is stronger
$521.5M
$9.0B
Stockholders' EquityBook value
$4.1B
$9.7B
Total Assets
$6.3B
$19.6B
Debt / EquityLower = less leverage
0.13×
0.92×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ITT
ITT
RPRX
RPRX
Q4 25
$1.7B
$618.7M
Q3 25
$516.4M
$938.9M
Q2 25
$467.9M
$631.9M
Q1 25
$439.8M
$1.1B
Q4 24
$439.3M
$929.0M
Q3 24
$460.9M
$950.1M
Q2 24
$425.5M
$1.8B
Q1 24
$423.0M
$843.0M
Total Debt
ITT
ITT
RPRX
RPRX
Q4 25
$521.5M
$9.0B
Q3 25
$577.7M
$8.9B
Q2 25
$622.5M
$8.0B
Q1 25
$4.5M
$7.6B
Q4 24
$232.6M
$7.6B
Q3 24
$467.8M
$7.6B
Q2 24
$190.0M
$7.6B
Q1 24
$230.5M
$6.1B
Stockholders' Equity
ITT
ITT
RPRX
RPRX
Q4 25
$4.1B
$9.7B
Q3 25
$2.7B
$9.6B
Q2 25
$2.6B
$9.5B
Q1 25
$2.8B
$9.8B
Q4 24
$2.8B
$10.3B
Q3 24
$2.7B
$10.3B
Q2 24
$2.6B
$9.8B
Q1 24
$2.6B
$9.9B
Total Assets
ITT
ITT
RPRX
RPRX
Q4 25
$6.3B
$19.6B
Q3 25
$5.1B
$19.3B
Q2 25
$5.0B
$18.3B
Q1 25
$4.8B
$17.6B
Q4 24
$4.7B
$18.2B
Q3 24
$4.9B
$18.0B
Q2 24
$4.4B
$17.7B
Q1 24
$4.4B
$16.1B
Debt / Equity
ITT
ITT
RPRX
RPRX
Q4 25
0.13×
0.92×
Q3 25
0.22×
0.93×
Q2 25
0.24×
0.84×
Q1 25
0.00×
0.78×
Q4 24
0.08×
0.74×
Q3 24
0.17×
0.74×
Q2 24
0.07×
0.78×
Q1 24
0.09×
0.62×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ITT
ITT
RPRX
RPRX
Operating Cash FlowLast quarter
$227.8M
$827.1M
Free Cash FlowOCF − Capex
$187.4M
FCF MarginFCF / Revenue
17.8%
Capex IntensityCapex / Revenue
3.8%
Cash ConversionOCF / Net Profit
1.73×
3.86×
TTM Free Cash FlowTrailing 4 quarters
$547.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ITT
ITT
RPRX
RPRX
Q4 25
$227.8M
$827.1M
Q3 25
$173.9M
$702.6M
Q2 25
$153.7M
$364.0M
Q1 25
$113.4M
$596.1M
Q4 24
$223.2M
$742.5M
Q3 24
$123.9M
$703.6M
Q2 24
$157.7M
$658.2M
Q1 24
$57.8M
$664.6M
Free Cash Flow
ITT
ITT
RPRX
RPRX
Q4 25
$187.4M
Q3 25
$146.2M
Q2 25
$137.3M
Q1 25
$76.6M
Q4 24
$186.8M
Q3 24
$87.3M
Q2 24
$134.5M
Q1 24
$30.1M
FCF Margin
ITT
ITT
RPRX
RPRX
Q4 25
17.8%
Q3 25
14.6%
Q2 25
14.1%
Q1 25
8.4%
Q4 24
20.1%
Q3 24
9.9%
Q2 24
14.8%
Q1 24
3.3%
Capex Intensity
ITT
ITT
RPRX
RPRX
Q4 25
3.8%
Q3 25
2.8%
Q2 25
1.7%
Q1 25
4.0%
Q4 24
3.9%
Q3 24
4.1%
Q2 24
2.6%
Q1 24
3.0%
Cash Conversion
ITT
ITT
RPRX
RPRX
Q4 25
1.73×
3.86×
Q3 25
1.37×
2.44×
Q2 25
1.27×
12.06×
Q1 25
1.05×
2.50×
Q4 24
1.76×
3.57×
Q3 24
0.77×
1.29×
Q2 24
1.32×
6.45×
Q1 24
0.52×
139.10×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ITT
ITT

Industrial Process$423.1M40%
Motion Technologies$360.8M34%
Connect Control Technologies$271.2M26%

RPRX
RPRX

Financial Royalty Assets$592.4M95%
Royalty Income Other$29.6M5%

Related Comparisons